AtriCure Announces Angie Wirick as Chief Financial Officer
August 06 2020 - 4:00PM
Business Wire
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments
for atrial fibrillation (Afib) and left atrial appendage (LAA)
management, announced today that Andy Wade is stepping down from
the position of Chief Financial Officer (CFO) for personal reasons
and moving into an advisory role through March 5, 2021. Angie
Wirick, current Vice President of Finance, has been promoted to CFO
effective immediately.
“On behalf of our team at AtriCure and our Board of Directors, I
want to thank Andy for his contributions to our company over the
past 13 years,” said Michael Carrel, President and Chief Executive
Officer of AtriCure. “Andy has been instrumental to our global
success and position of financial strength. Through his strong
leadership, we achieved critical milestones to build AtriCure’s
foundation and position our company for accelerated growth. These
accomplishments have propelled our company to new levels of success
and created significant shareholder value.”
“I am honored to have been a part of a tremendous team and
world-class culture at AtriCure,” said Mr. Wade. “It has been a
true privilege to work alongside colleagues who are passionately
committed to our mission of improving patient lives and to see the
growth of our impact in reducing the Afib epidemic around the
world. While stepping down was a difficult decision, I am looking
forward to moving into an advisory role and spending more time with
my family.”
Mr. Carrel also stated, “We are excited to have Angie as our new
CFO. Angie has been an integral part of our team for six years. I
congratulate Angie on the new role and look forward to continuing
to work with her on our strategic initiatives and leading the
company into the future.”
Ms. Wirick joined AtriCure in July 2014 and most recently has
been the Vice President of Finance, responsible for the global
accounting and finance functions of the Company. Before AtriCure,
Ms. Wirick spent 12 years at Deloitte & Touche LLP in
managerial roles and began her career at Arthur Andersen LLP. Ms.
Wirick is a certified public accountant and holds a Bachelor of
Science in Accounting from the University of Dayton.
About AtriCure
AtriCure, Inc. provides innovative technologies for the
treatment of Afib and related conditions. Afib affects more than 33
million people worldwide. Electrophysiologists and cardiothoracic
surgeons around the globe use AtriCure technologies for the
treatment of Afib and reduction of Afib related complications.
AtriCure’s Isolator® Synergy™ Ablation System is the first and only
medical device to receive FDA approval for the treatment of
persistent Afib. AtriCure’s AtriClip Left Atrial Appendage (LAA)
Exclusion System products are the most widely sold LAA management
devices worldwide. AtriCure’s cryoICE is the first U.S. Food and
Drug Administration (FDA)-cleared cryo ablation probe for the
temporary ablation of peripheral nerves to block pain, providing
temporary pain relief in cardiac and thoracic procedures. For more
information, visit AtriCure.com or follow us on Twitter
@AtriCure.
Forward-Looking
Statements
This press release contains “forward-looking statements”– that
is, statements related to future events that by their nature
address matters that are uncertain. For details on the
uncertainties that may cause our actual results to be materially
different than those expressed in our forward-looking statements,
visit http://www.atricure.com/fls as
well as our Annual Reports on Form 10-K and Quarterly Reports on
Form 10-Q which contain risk factors. We do not undertake to update
our forward-looking statements. Actual results could differ
materially.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200806005998/en/
Lynn Pieper Lewis Gilmartin Group Investor Relations (415)
937-5402 lynn@gilmartinir.com
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Aug 2024 to Sep 2024
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Sep 2023 to Sep 2024